Approvals for medical devices may ease with new classification

The Central Drugs Standard Control Organisation’s (CDSCO’s) draft rules for re-classification of medical devices based on their risk profile has received wide support from the industry, as it will allow cetralaised, faster approval of high-risk equipment. The classification of medical devices are done at the state and central level based on the risk profile of the devices. For instance, the manufacturing of class A and B devices, which have lower risks involved, are cleared by the state governments. The production of class C and D devices are cleared by central agency CDSCO.

Prior to this draft, the classification of the devices were left to the discretion of the state governments, especially in cases of new non-classified devices. “In some cases, the companies have to face issues with state governments because their interpretation of the risk were different from the device manufacturers. Now, that ambiguity has been addressed to a large extent. It would reduce the delays in new product launches,” said head of medical device association, on condition of anonymity.

Experts said that the classification would be more beneficial for manufacturers than importers because the importers are already taking approval from CDSCO – where they have “strong inroads – for all kinds of devices.

Rajiv Nath, forum coordinator at association of Indian medical device industry (AiMeD) said that there’s an urgent need to create awareness about this classification. “We urge constant conferences and meetings with stakeholders to bring clarity for regulatory compliance needs and alignment as we find huge variances of interpretation of medical device rules between various state and central government regulators as manufacturers wade through a daunting maze of lengthy regulatory approval hurdles so that regulatory approvals can be expedited,” he said.

Experts said that there’s a need to constantly update the list so that its purpose doesn’t get defeated. For instance, if a product classification is not known, the manufacturer would not be able to submit its applications, and it will cause delays till the CDSCO is approached, and informed about the classification based on other jurisdictions like the US, EU or Singapore.

Related Posts

  • Pharma
  • January 22, 2025
  • 87 views
Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

As the “Trump 2.0 Era” begins in the United States, the world’s largest pharmaceutical market, attention is focused on its impact on the domestic pharmaceutical and biotech sectors. The industry…

  • Pharma
  • January 22, 2025
  • 106 views
Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

Jaipur:  The Narcotics Control Bureau seized narcotic tablets and capsules worth Rs 14 lakh during an operation in Jaipur on Tuesday, an official said. The Narcotics Control Bureau (NCB) said…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

Trump 2.0 Era: Pharma and Biotech Industries Eye Gains from Biosimilars and CDMO

Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

Narcotics worth Rs 14 lakh seized in Jaipur, one arrested

DCA raids illegal de-addiction centre in Hanamkonda

DCA raids illegal de-addiction centre in Hanamkonda

CCI Approves Merger Of Nine Pharma Entities With Sequent Scientific

CCI Approves Merger Of Nine Pharma Entities With Sequent Scientific

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

Glenmark Pharma share rises 2% as unit launches blood clotting drug

Glenmark Pharma share rises 2% as unit launches blood clotting drug